Pfiz­er says RSV shot to pro­tect in­fants may be avail­able by 2023-24 cold and flu sea­son

Pfiz­er’s vac­cine to pro­tect in­fants from RSV may be ap­proved be­fore the next cold and flu sea­son, the com­pa­ny said on Tues­day.

Reg­u­la­tors grant­ed RSVpreF, al­so known as PF-06928316, a pri­or­i­ty re­view for the pre­ven­tion of med­ical­ly at­tend­ed low­er res­pi­ra­to­ry tract ill­ness (MA-LR­TI) caused by RSV in in­fants. The shot would be ad­min­is­tered dur­ing preg­nan­cy to pro­tect in­fants from birth to 6 months old.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER